TAK 071

Drug Profile

TAK 071

Alternative Names: TAK-071

Latest Information Update: 23 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Takeda
  • Class Antidementias; Nootropics
  • Mechanism of Action Muscarinic M1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 01 Dec 2016 Takeda initiates enrolment in a phase Ib pharmacodynamics trial in Healthy volunteers in USA (PO) (NCT02918266)
  • 27 Sep 2016 Takeda plans a phase Ib pharmacodynamics trial in Healthy volunteers in USA (PO) (NCT02918266)
  • 01 May 2016 Phase-I clinical trials in Alzheimer's disease in USA (PO) (NCT02769065)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top